RESUMEN
Using a patient chart review process, we conducted a retrospective study to describe the frequency of allergic reactions in individuals with haemophilia B receiving factor IX (FIX) replacement therapy. The number of allergic reactions in individuals receiving a recombinant FIX (rFIX) product (BeneFix(®)) was then compared with the number of reactions in patients receiving plasma-derived FIX (pdFIX) products. Of the 180 subjects in the study, 163 received rFIX, 88 received pdFIX; 71 received both product types. A total of seven (3.89%) subjects had a moderate or severe allergic reaction to a FIX product (95% confidence interval [CI], 1.06-6.71%). Among those receiving rFIX, four subjects (2.45%) had an allergic reaction (95% CI, 0.08-4.83%). Of individuals taking pdFIX products, three (3.41%) developed an allergic reaction (95% CI, 0-7.20%). It was noted that three (1.84%) of those taking rFIX developed an inhibitor to FIX (95% CI, 0-3.90%), while four (4.55%) of those receiving a pdFIX product developed an inhibitor (95% CI, 0.19-8.90%). Inhibitor development was frequently associated with allergic reaction. These results provide evidence that there is no difference in the frequency of allergic reactions or inhibitor development in individuals receiving rFIX compared with those receiving pdFIX concentrates. The current study and a previous study of similar design have now compared the rate of allergic reactions associated with rFIX and pdFIX concentrates has now been compared in a total of 414 subjects; this represents the largest collection of data to date on this rare complication of haemophilia B therapy.
Asunto(s)
Factor IX/efectos adversos , Hemofilia B/tratamiento farmacológico , Hipersensibilidad Inmediata/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Inhibidores de Factor de Coagulación Sanguínea/sangre , Niño , Preescolar , Europa (Continente)/epidemiología , Factor IX/uso terapéutico , Femenino , Humanos , Hipersensibilidad Inmediata/etiología , Incidencia , Masculino , Persona de Mediana Edad , América del Norte/epidemiología , Estudios Retrospectivos , Adulto JovenRESUMEN
Lack of detailed natural history and outcomes data for neonates and toddlers with haemophilia hampers the provision of optimal management of the disorder. We report an analysis of prospective data collected from 580 neonates and toddlers aged 0-2 years with haemophilia enrolled in the Universal Data Collection (UDC) surveillance project of the Centers for Disease Control and Prevention (CDC). This study focuses on a cohort of babies with haemophilia whose diagnosis was established before the age of two. The mode of delivery, type and severity of haemophilia, onset and timing of haemorrhages, site(s) of bleeding, provision of prophylaxis with coagulation factor replacement therapy, and the role played by the federally funded Haemophilia Treatment Centers (HTC) in the management of these infants with haemophilia were evaluated. Seventy-five per cent of haemophilic infants were diagnosed early, in the first month of life, especially those with a family history or whose mothers were known carriers; infants of maternal carriers were more likely to be delivered by C-section. Involvement of an HTC prior to delivery resulted in avoidance of the use of assisted deliveries with vacuum and forceps. Bleeding from the circumcision site was the most common haemorrhagic complication, followed by intra- and extra-cranial haemorrhages and bleeding from heel stick blood sampling. Eight per cent of the infants were administered factor concentrate within 24 h of birth; more than half were treated to prevent bleeding. This study highlights the significant rate and the sites of initial bleeding unique to very young children with haemophilia and underscores the need for research to identify optimal evidence-based recommendations for their management.
Asunto(s)
Parto Obstétrico , Hemofilia A/diagnóstico , Hemorragias Intracraneales/epidemiología , Edad de Inicio , Preescolar , Medicina Basada en la Evidencia , Femenino , Hemofilia A/epidemiología , Humanos , Lactante , Recién Nacido , Hemorragias Intracraneales/prevención & control , Masculino , Embarazo , Estudios Prospectivos , Estados Unidos/epidemiologíaRESUMEN
PURPOSE: To assess thiopurine S-methyltransferase (TPMT) phenotype and genotype in patients who were intolerant to treatment with mercaptopurine (MP) or azathioprine (AZA), and to evaluate their clinical management. PATIENTS AND METHODS: TPMT phenotype and thiopurine metabolism were assessed in all patients referred between 1994 and 1999 for evaluation of excessive toxicity while receiving MP or AZA. TPMT activity was measured by radiochemical analysis, TPMT genotype was determined by mutation-specific polymerase chain reaction restriction fragment length polymorphism analyses for the TPMT*2, *3A, *3B, and *3C alleles, and thiopurine metabolites were measured by high-performance liquid chromatography. RESULTS: Of 23 patients evaluated, six had TPMT deficiency (activity < 5 U/mL of packed RBCs [pRBCs]; homozygous mutant), nine had intermediate TPMT activity (5 to 13 U/mL of pRBCs; heterozygotes), and eight had high TPMT activity (> 13.5 U/mL of pRBCs; homozygous wildtype). The 65.2% frequency of TPMT-deficient and heterozygous individuals among these toxic patients is significantly greater than the expected 10% frequency in the general population (P <.001, chi(2)). TPMT phenotype and genotype were concordant in all TPMT-deficient and all homozygous-wildtype patients, whereas five patients with heterozygous phenotypes did not have a TPMT mutation detected. Before thiopurine dosage adjustments, TPMT-deficient patients experienced more frequent hospitalization, more platelet transfusions, and more missed doses of chemotherapy. Hematologic toxicity occurred in more than 90% of patients, whereas hepatotoxicity occurred in six patients (26%). Both patients who presented with only hepatic toxicity had a homozygous-wildtype TPMT phenotype. After adjustment of thiopurine dosages, the TPMT-deficient and heterozygous patients tolerated therapy without acute toxicity. CONCLUSION: There is a significant (> six-fold) overrepresentation of TPMT deficiency or heterozygosity among patients developing dose-limiting hematopoietic toxicity from therapy containing thiopurines. However, with appropriate dosage adjustments, TPMT-deficient and heterozygous patients can be treated with thiopurines, without acute dose-limiting toxicity.
Asunto(s)
Antimetabolitos Antineoplásicos/efectos adversos , Azatioprina/efectos adversos , Mercaptopurina/efectos adversos , Metiltransferasas/deficiencia , Metiltransferasas/genética , Polimorfismo de Longitud del Fragmento de Restricción , Trombocitopenia/inducido químicamente , Adolescente , Adulto , Niño , Preescolar , Femenino , Genotipo , Hospitalización , Humanos , Lactante , Masculino , Metiltransferasas/metabolismo , Neoplasias/tratamiento farmacológico , Fenotipo , Transfusión de Plaquetas , Factores de Riesgo , Trombocitopenia/genéticaRESUMEN
The purpose of this report is to describe the tolerability and activity of the combination of high-dose cytosine arabinoside (Ara-C) given at the maximum tolerated dose of 36 g/m2, together with high doses of etoposide in relapsed and refractory childhood acute leukemias. Eighteen children with relapsed or refractory acute leukemia were treated with Ara-C 3 g/m2 every 12 h on days 1-6, followed by etoposide 400 mg/m2 on days 7-9 (HDAC/VP-16). Eight children with refractory disease received HDAC/VP-16 as salvage induction therapy after failing conventional induction regimens; four of five refractory ANLL patients (80%) had a complete response (CR) after HDAC/VP-16 therapy. Ten patients received HDAC/VP-16 as post-remission intensification therapy; five patients (four ANLL, one relapsed ALL) remain in second CR at 56, 26, 9, 5 and 2 months. Toxicities were primarily hematologic and dermatologic. Seven patients (39%) developed bacterial or fungal infections; four patients developed grade 3 or 4 acral erythema. No patient died of therapy-related toxicity. The combination of 36 g/m2 cytosine arabinoside and 1200 mg/m2 etoposide is an effective regimen for children with relapsed or refractory acute nonlymphocytic leukemia, with tolerable toxicities; the absence of anthracyclines makes this regimen suitable for patients who have previously received maximal doses of anthracyclines or who have evidence of cardiac dysfunction. Further evaluation of this regimen in acute nonlymphocytic leukemia is presently being investigated.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Leucemia Mieloide/tratamiento farmacológico , Enfermedad Aguda , Adolescente , Antraciclinas , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Enfermedades de la Médula Ósea/inducido químicamente , Niño , Preescolar , Contraindicaciones , Citarabina/administración & dosificación , Citarabina/efectos adversos , Etopósido/administración & dosificación , Etopósido/efectos adversos , Femenino , Humanos , Lactante , Infecciones/etiología , Leucemia Mieloide/mortalidad , Masculino , Terapia Recuperativa , Resultado del TratamientoRESUMEN
Critical to providing cancer therapy to children in rural areas is finding dependable sources of therapy near the patients' homes. In this study, comparison was made of 668 visits by 24 patients to nearby private practitioners, who carried out 70% of the therapy, with 712 visits by 22 other patients for whom all care was managed by pediatric hematologist-oncologists. There was no significant difference by Wilcoxon rank sum test between the two groups in the accuracy with which protocol rules were followed, in the incidence of neutropenia, infection, fever, thrombocytopenia, drug toxicity, or the proportion of days hospitalized. The findings indicate that the private practitioners participating in a shared-management system were a dependable resource for providing 70% of the total cancer therapy to these patients.
Asunto(s)
Servicios de Salud Comunitaria , Atención a la Salud , Neoplasias/terapia , Antineoplásicos/efectos adversos , Niño , Humanos , Iowa , Evaluación de Procesos y Resultados en Atención de SaludRESUMEN
Human serum augments the ability of bacterial lipopolysaccharide (endotoxin) or partially-purified C5-derived chemotactic fragments (C5-fr) to induce the monocyte procoagulant activity (PCA) in vitro. Both autologous and pooled sera induced PCA in the target cell population. Dose response curves revealed a detectable response in PCA with as little as 0.1% serum (v:v) in cell suspensions incubated for 4-6 hours before assay of PCA. Heat-inactivation experiments showed that enhancing activity of serum for both endotoxin and C5-fr induced-PCA could be destroyed by heating at 56 degrees C, with the greater part of the activity lost during the first 30 minutes of heating. The enhancing serums studied contained no endotoxin as measured by the Limulus amebocyte lysate assay and these serums failed to induce aggregation of neutrophils, a sensitive measure for the presence of complement-derived chemotactic fragments such as C5a. Serum without endotoxin or C5-fr also induced a variable increase in PCA and this inducing activity could also be abolished by heating, whereas the ability of endotoxin alone (10 micrograms/ml) to induce PCA was unaffected by similar heat-treatment. The procoagulant appeared to function as tissue factor in one-stage clotting assays using deficient substrate plasmas. Lymphocytes stimulated by serum and later washed failed to amplify monocyte tissue factor whereas lymphocytes exposed to endotoxin retained the ability to amplify monocyte tissue factor. These results suggest a role for serum in the modulation in vitro of monocyte procoagulant.
Asunto(s)
Factores de Coagulación Sanguínea/biosíntesis , Complemento C5/análogos & derivados , Endotoxinas/farmacología , Lipopolisacáridos/farmacología , Monocitos/metabolismo , Adulto , Complejo Antígeno-Anticuerpo/fisiología , Relación Dosis-Respuesta a Droga , Calor , Humanos , Inmunoglobulinas/farmacología , Técnicas In Vitro , Cinética , Monocitos/efectos de los fármacosAsunto(s)
Accidentes de Aviación , Aeronaves , Heridas y Lesiones , Medicina Aeroespacial , Humanos , Medición de RiesgoRESUMEN
ReFacto is a recombinant B-domain-deleted, monoclonal antibody-purified, solvent-detergent-treated factor VIII (BDDrFVIII) with no albumin added to the final formulation. Although ReFacto has been shown to be bioequivalent to a plasma-derived FVIII product (Hemophil-M) in a randomized, crossover pharmacokinetic (PK) study, the comparability of ReFacto with the full-length (complete sequence) recombinant FVIII (FLrFVIII, Advate) product has not been previously examined in this manner. The primary objective of this study was to compare the PKs of ReFacto with those of Advate in patients with severe haemophilia A. This was a third-party unblinded, randomized, multicentre, two-period crossover PKs study of ReFacto and Advate in subjects with severe haemophilia A (FVIII:C < or =1%). Blood samples were collected over a 48-h period after i.v. administration of each of the FVIII products. FVIII:C was determined using the chromogenic substrate assay (CSA) in a central laboratory. The plasma FVIII:C PK parameters of ReFacto and Advate were determined using non-compartmental analysis. Bioequivalence was assessed on maximum plasma concentration (C(max)) and the area under the plasma concentration vs. time curves (AUCs) using an anova. The two products were judged to be equivalent if the 90% confidence limits of the ratio of the geometric mean values of C(max) and AUCs fell within the interval of 80-125%. Results from this PKs comparison of two different rFVIII products, using chromogenic substrate assay to measure FVIII:C, showed that ReFacto and Advate are bioequivalent to each other.
Asunto(s)
Coagulantes/farmacocinética , Factor VIII/farmacocinética , Hemofilia A/tratamiento farmacológico , Adulto , Anciano , Área Bajo la Curva , Coagulantes/administración & dosificación , Estudios Cruzados , Ética en Investigación , Factor VII/administración & dosificación , Factor VII/farmacocinética , Factor VIII/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/farmacocinética , Equivalencia TerapéuticaRESUMEN
Human peripheral blood mononuclear cells exposed to the synthetic chemotactic factor n-formyl-methionyl-leucyl-phenylalanine (FMLP) were enhanced in their ability to generate superoxide anion (O-2), hydroxyl radical (OH.), and chemiluminescence when later exposed to phorbol myristate acetate (PMA). When compared to oxidative responses of cells treated with PMA alone, the degree of enhancement by pretreatment with FMLP was 1.85-fold for O-2 generation, 1.73-fold for OH. production, and 1.34-fold for chemiluminescence. Similarly, pretreatment of mononuclear leukocytes with 5% zymosan-activated serum also enhanced subsequent oxidative responses of cells exposed to PMA. FMLP did not enhance subsequent O-2 release or chemiluminescence by mononuclear leukocytes stimulated by opsonized zymosan or 20 mM sodium fluoride (F-), demonstrating that the O-2 generating system of monocytes stimulated by phagocytosis or F- is not susceptible to chemotactic factor regulation in a manner similar to the system stimulated by PMA. The latter system, like that of neutrophils, is susceptible to regulation by cellular processes activated during an initial encounter with chemoattractants. These processes may provide a mechanism to amplify oxidative responses at sites of infection or inflammation, leading to enhanced efficiency of microbicidal activity or increased tissue damage in vivo.
Asunto(s)
Factores Quimiotácticos/farmacología , Monocitos/metabolismo , Oxígeno/sangre , Adulto , Radicales Libres , Humanos , Hidróxidos/sangre , Radical Hidroxilo , Técnicas In Vitro , Mediciones Luminiscentes , N-Formilmetionina Leucil-Fenilalanina/farmacología , Oxidación-Reducción , Superóxidos/sangre , Acetato de Tetradecanoilforbol/farmacologíaRESUMEN
Various n-formylated peptides function as receptor-specific chemoattractants for both granulocytes and monocytes. Because these agents are important tools in the study of leukocyte function in vitro, we chose to examine their effects on leukocyte procoagulant activity. The synthetic chemotactic peptide N-formyl-methionyl-leucyl phenylalanine (FMLP) induces a fourfold increase in procoagulant activity (PCA) in cultured human monocytes at an optimal dose of 5 X 10(-9) mol/L, whereas higher doses inhibit PCA response. Although nonadherent lymphocytes are not absolutely required for PCA expression, their presence significantly amplifies monocyte PCA. Irradiation of nonadherent lymphocytes before mixing them with FMLP and adherent cells abolishes their ability to amplify PCA. Kinetic studies demonstrate an increase in optimal dose FMLP-stimulated PCA over time whereas high-dose inhibition of PCA generation occurs at various incubation times. Cell viability is unaffected by inhibitory concentrations of FMLP. Supernates from high-dose FMLP-stimulated cells fail to inhibit later expression of PCA by cells exposed to endotoxin. The cellular procoagulant remains cell-bound and exhibits characteristics of thromboplastin (tissue factor), including inhibition by concanavalin A and phospholipase C as well as the ability to shorten the clotting times of factor VIII but not factor VII-deficient substrate plasmas. These results suggest a complex system of lymphoid cell regulation of procoagulant generation by monocytes exposed to various chemotactic peptides in vitro.
Asunto(s)
Coagulación Sanguínea/efectos de los fármacos , Monocitos/efectos de los fármacos , N-Formilmetionina Leucil-Fenilalanina/farmacología , Factores Quimiotácticos/farmacología , Endotoxinas/farmacología , Humanos , Cinética , Activación de Linfocitos/efectos de los fármacos , Tromboplastina/biosíntesisRESUMEN
Many bleeding episodes in hemophilia are thought to be related to ambient stress. The evidence in support of this hypothesis comes from a variety of anecdotal and clinical reports. Whether or not stress leads to bleeding has had little direct study in a prospective way, however, and methodological problems affect most of the studies in this field. This paper examines the evidence in support of this hypothesis and suggests ways to improve research relating stress to bleeding.
Asunto(s)
Hemofilia A/complicaciones , Hemorragia/etiología , Estrés Psicológico/complicaciones , Niño , Hemofilia A/psicología , Hemofilia B/complicaciones , Hemofilia B/psicología , Humanos , Masculino , Relaciones Padres-HijoRESUMEN
Disorders that predispose children to venous thrombosis include inherited abnormalities of antithrombin III, protein S, protein C, fibrinogen, and plasminogen. Arterial thrombosis may result from disorders that produce endothelial damage, abnormal vascular flow, or increased platelet aggregation. We present here a case of a child who had recurrent thromboses and discuss the evaluation and management of such patients.
Asunto(s)
Deficiencia de Antitrombina III , Trastornos de la Coagulación Sanguínea/sangre , Adulto , Trastornos de la Coagulación Sanguínea/genética , Infarto Cerebral/sangre , Infarto Cerebral/genética , Niño , Salud de la Familia , Femenino , Glicoproteínas/deficiencia , Humanos , Masculino , Linaje , Deficiencia de Proteína C , Proteína S , Embolia Pulmonar/sangre , Embolia Pulmonar/genética , Recurrencia , Tromboflebitis/sangre , Tromboflebitis/genéticaRESUMEN
To date the only point mutations demonstrated to cause hemophilia are C to T transitions in TaqI sites. These were detected by screening Southern blots with cloned factor VIII probes. During the development of improved methods for detecting and analyzing mutations in genomic DNA, a novel G to C transversion mutation has been identified. This rare transversion results in a missense mutation, with proline being substituted for arginine in one of the active domains of the factor VIII molecule. The results suggest that the improved methods will be useful for detecting mutations in hemophilia as well as in other genetic disorders. In this method, specific DNA sequences in genomic DNA are amplified using oligonucleotide primers and a heat-resistant DNA polymerase. Mutations are detected and localized in the amplified samples by RNase A cleavage, and the altered region is then sequenced.
Asunto(s)
Secuencia de Bases , Análisis Mutacional de ADN , Factor VIII/genética , Amplificación de Genes , Hemofilia A/genética , Clonación Molecular , Análisis Mutacional de ADN/métodos , Hemofilia A/sangre , Humanos , Masculino , Ribonucleasas/genéticaRESUMEN
We conducted a retrospective survey of our experience with central venous access devices (CVADs) implanted in children with haemophilia seen at the Vanderbilt Hemostasis-Thrombosis Clinic from 1986 to 2000. Following discussion with parents on the merits and risks associated with the use of CVADs for immune tolerance induction or factor prophylaxis, catheters were inserted under sterile technique in the operating room. One nurse provided demonstration and teaching about catheter care and access. Thirty central venous catheters were inserted in 22 children. Our survey revealed that the two most common complications associated with central venous catheters were bacteraemia and thrombosis. We found a sepsis rate of 0.30/1000 catheter-days or one episode of bacteraemia for every 3346 days of catheter use. The thrombosis rate of our cohort was 0.13/1000 catheter-days or one episode of thrombosis for every 7529 days of catheter use. Uncomplicated venous access is essential in children with severe haemophilia who require prophylaxis or immune tolerance induction. While infection was the most common complication observed in our series, we experienced a lower overall infection rate than several reported series. Catheter thrombosis and subsequent obstruction may occur as a result of intraluminal fibrin deposits. We conclude that the use of implantable central venous catheters is an effective method for accessing children with haemophilia. We accept that the benefits of CVADs in the treatment of paediatric haemophilia patients outweigh the previously documented risks. Future prospective studies should be designed to define all associated risks and to determine effective strategies to reduce them.
Asunto(s)
Cateterismo Venoso Central/efectos adversos , Catéteres de Permanencia/efectos adversos , Hemofilia A/terapia , Hemofilia B/terapia , Adolescente , Adulto , Bacteriemia/etiología , Niño , Preescolar , Contaminación de Equipos , Factor IX/administración & dosificación , Factor VIII/administración & dosificación , Humanos , Lactante , Masculino , Estudios Retrospectivos , Trombosis/etiologíaRESUMEN
Radioimmunoassays for both human copper-zinc and manganous superoxide dismutases (Cu-Zn SOD and Mn SOD, respectively) have been developed, validated, and utilized to measure the concentrations of these enzymes in cultured monocytes. Monocyte Mn SOD increased 4.7-fold over basal during 3 days of culture, an increase that was markedly enhanced by stimulation with bacterial lipopolysaccharide (LPS). Cu-Zn SOD showed a transient decrease over the culture period but was unaffected by LPS. Stimulation with muramyl dipeptide had minimal effect on Mn SOD and no effect on Cu-Zn SOD during culture, even at a concentration capable of activating the monocytes, as defined by zymosan-induced superoxide production.
Asunto(s)
Monocitos/enzimología , Acetilmuramil-Alanil-Isoglutamina/farmacología , Inducción Enzimática , Humanos , Lipopolisacáridos/farmacología , Radioinmunoensayo/métodos , Estimulación Química , Superóxido Dismutasa/análisis , Zimosan/farmacologíaRESUMEN
Systemic metastases from central nervous system germinomas are exceedingly rare, and when they occur lead to fatal outcomes. The authors report the case of a 10-year-old girl who presented with metastatic involvement of the rib and pelvis 2.5 years after surgical resection and radiation therapy for a suprasellar dysgerminoma. After combination chemotherapy, the patient remains disease-free 30 months after relapse. This case provides evidence that chemotherapy can be an effective therapeutic alternative to the use of radiation in the treatment of children with extracranial germinomas.
Asunto(s)
Neoplasias Óseas/secundario , Neoplasias Encefálicas/patología , Disgerminoma/patología , Neoplasias Encefálicas/terapia , Niño , Disgerminoma/secundario , Disgerminoma/terapia , Femenino , Humanos , Ilion , CostillasRESUMEN
We report on a family with a history of venous thromboembolism associated with fibrinogen Paris V (fibrinogen Aalpha-Arg554-->Cys). Ten members experienced thrombotic events, including 4 with fatal pulmonary emboli. Pulmonary embolism was the presenting feature in 4. Those with the mutation and a history of thrombosis had somewhat higher fibrinogen concentrations than those with the mutation and no thrombosis (294 +/- 70 mg/dL vs 217 +/- 37 mg/dL, respectively). The Paris V mutation consistently caused a prolongation of the reptilase time, and fibrin clots containing the abnormal fibrinogen were more translucent than normal clots. Given the early onset of symptoms and the initial presentation with pulmonary embolism in some family members, it was justifiable to offer prophylactic anticoagulation with warfarin to carriers of the mutation. Fibrinogen Paris V has now been reported in 4 apparently unrelated families, indicating that it is a relatively common cause of dysfibrinogenemia-associated thrombosis.
Asunto(s)
Fibrinógenos Anormales/genética , Trombofilia/genética , Adolescente , Adulto , Femenino , Humanos , Persona de Mediana Edad , Mutación , LinajeRESUMEN
To describe the patterns of bleeding and clotting factor concentrate use in boys with haemophilia over a 6-month period, daily diary records of bleeding, factor use, levels of physical activity, chore performance and school attendance were collected from parents of 96 males between 4 and 17 years of age with haemophilia A or B followed at six comprehensive haemophilia treatment centres in Massachusetts, Rhode Island and Tennessee. 14 243 person days were available for analysis. The sample cohort averaged approximately nine bleeding episodes (1.5 per months), almost two-thirds of which were haemarthroses. 44% of bleeds were associated with injury and the average duration was 1.4 days. New bleeding episodes were significantly more likely to begin on weekdays (Monday-Thursday) than on weekends (Friday-Sunday). Boys with more severe disease had significantly more bleeding episodes and a higher frequency of haemarthroses. Boys with the most severe disease were also more likely to have joints involved when they bled and to have more spontaneous bleedings without apparent preceding trauma. Bleeding was associated with increased school absence, decreased levels of physical activity and decreased rates of household task performance. Relatively high rates of bleeding associated with trauma suggest the need for preventive interventions.